TMCnet News
Fast-Growing Oncology Startup OncoLens Secures $7.25 Million Series A FundingATLANTA, Jan. 13, 2021 /PRNewswire/ -- OncoLens, a pioneer in tumor board and cancer treatment planning solutions, announced today that it has raised a $7.25 million Series A investment from BIP Capital, Martin Ventures, and SeedToB Capital, a new healthcare artificial intelligence (AI) venture fund launched by former Jvion Co-founders Shantanu Nigam and Ritesh Sharma. OncoLens brings collaborative and personalized treatment planning to the cancer patient through data integration and decision support. It helps cancer programs and their multidisciplinary teams of specialists collaborate effectively while easily aggregating patient-specific data in a HIPAA-compliant manner across different EMR/clinical/genetics information systems. Patient-specific clinical trials at a facility or its affiliates, NCCN/ASCO guidelines, and the latest research are also automatically identified for each case to support the care team in making the best decision for the patient. "The new investment round will enable us to further capitalize on our position as a leader in the tumor board and cancer treatment planning software industry," said Anju Mathew, CEO of OncoLens. "We're excited to continue our work with BIP Capital and our new investors Martin Ventures and SeedToB Capital. Their combined deep expertise in healthcare and AI will help catalyze both our product development and market expansion efforts." OncoLens is being used or implemented across several National Cancer Institute-designated Cancer Centers and some of the largest U.S. healthcare delivery networks. The company has received significant market recognition, with studies showcased in the Association of Community Cancer Centers' Oncology Journal, Journal of Registry Management, American Society of Clinical Oncology, and others. "We were an early investor in OncoLens and we're proud of its rapid growth and commitment to improving healthcare through technology," said Mark Buffington, co-founder and CEO of BIP Capital and lead investor of its growing portfolio of Healthcare IT investments. "We're confident OncoLens will increasingly become part of the new norm in terms of how care providers collaborate efficiently and effectively with one another." "OncoLens is enabling better outcomes for cancer patients," said Devin Carty, CEO of Martin Ventures. "The need for new, cutting-edge technologies has never been more important to ultimately winning the fight against cancer. We are excited to partner with Anju and the rest of the OncoLens team to extend and expand clinical trials, precision medicine, and multidisciplinary care to cancer patients." "Tumor boards and care collaboratio are within a space needing much innovation," said Shantanu Nigam, managing partner of SeedToB Capital. "OncoLens is stepping up and leading this charge with a very innovative approach under stellar leadership. We're extremely excited to welcome OncoLens to our portfolio." The funding announcement comes during a week when many healthcare investors and innovators are attending the 39th Annual J.P. Morgan Health Care Conference virtually (social media hashtag #JPM21). A focal area of the event is telemedicine and virtual collaboration tools to help healthcare providers better meet the needs of patients in a mobile and digitally connected world. In 2020, OncoLens was named among the top 10 most innovative companies by the Technology Association of Georgia. OncoLens currently serves more than 8,000 cancer care providers across the country. About BIP Capital About Martin Ventures About SeedToB Capital About OncoLens Media Contact: View original content:http://www.prnewswire.com/news-releases/fast-growing-oncology-startup-oncolens-secures-7-25-million-series-a-funding-301207721.html SOURCE OncoLens |